(VIANEWS) – NeuroMetrix (NURO) investors saw their stock prices plunge 20.61% to EUR0.53 at 14:01 EST Thursday afternoon, continuing their recent downslide after two consecutive sessions of gains. This brings NeuroMetrix close to its 52-week low of EUR0.47; similarly, NASDAQ was down 1.81% at EUR12,588.80 with NeuroMetrix closing out with EUR0.67 which is 69.57% below its 52-week high of EUR2.18.
About NeuroMetrix
NeuroMetrix is a commercial stage neurotechnology company that designs, builds, and markets medical devices to stimulate and analyze nerve response for diagnostic and therapeutic use. Their primary products – DPNCheck, Quell, and ADVANCE system – are used by healthcare providers for peripheral neuropathy evaluation, chronic pain management and nerve conduction studies. Their customer base includes managed care organizations, primary care physicians as well as specialists from different fields like pain medicine, neurology and physical medicine and rehabilitation. NeuroMetrix was founded in 1996 and resides out of Woburn Massachusetts.
Yearly Analysis
NeuroMetrix’s stock is trading at EUR0.53, well below its 52-week low of EUR0.60. Additionally, EBITDA stands at EUR7.12, providing a measure of its financial performance.
Investment considerations require considering both NeuroMetrix’s financials and market trends. While NeuroMetrix’s current stock price may be below its 52-week low, its financial performance may have improved since that point – however without additional information it can be hard to assess whether NeuroMetrix represents an attractive investment opportunity or not.
Investors should also keep the overall health and economic outlook of the market and economy in mind, as these can impact individual stock performance. Furthermore, investors are advised to conduct additional research and analysis prior to making any investment decisions, including reviewing financial statements of companies as well as industry trends.
Technical Analysis
NeuroMetrix, a medical device company, is currently experiencing a steep drop in its stock value with prices well below both its 50-day and 200-day moving averages of EUR0.70 and EUR1.17 respectively. Though its stock has been on a gradual downward trend for some time now, its volume has significantly outstripped this average volume – currently sitting at 208,417 which represents a 446% increase versus 38157 as recently reported volume levels indicate.
NeuroMetrix has displayed relatively stable performance over the last month and quarter, with intraday volatility averages of 0.28% and 3.48%, respectively. Their highest monthly amplitude of average volatility reached 4.62% which suggests some level of market uncertainty.
NeuroMetrix’s stock currently appears to be oversold (=20), according to the stochastic oscillator, an indicator of overbought/oversold conditions, according to its stochastic oscillator indicator. This may signal undervaluation that could present investors with potential investment opportunities; however, stock prices can also be affected by market sentiment, company performance and global events so investors should conduct thorough research prior to making any definitive investments decisions.
Quarter Analysis
Based on this data, investors must remain cautious regarding a stock’s revenue growth. A year-on-year quarterly revenue growth decline of 22.6% indicates that company revenues may be decreasing significantly and could indicate that the business may be facing difficulties in generating revenues and expanding.
Furthermore, with twelve trailing month revenue now standing at 7.2 million it suggests that revenue is not increasing at an optimal pace due to factors such as decreased demand for products or services offered by the company, increased competition within their industry or operational issues.
Before investing, investors should carefully evaluate these factors and monitor revenue growth over the coming quarters in order to see if it can turn things around. Furthermore, it may be worthwhile to compare this company’s growth with that of competitors within its industry and determine where its standing lies within it.
Equity Analysis
NeuroMetrix’s Earnings Per Share (EPS) figure for the past year – EUR-0.72 – suggests it has experienced a loss per share over that timeframe and may not be producing sufficient profits to fund operations and pay dividends to its shareholders.
Additionally, the company’s return on equity (ROE) of negative -24.14% suggests that they have not generated profits relative to shareholder’s equity – this indicates they may not be using their funds effectively to generate returns for them. This could indicate they are not effectively allocating them.
Potential investors should proceed with caution when investing in NeuroMetrix. Past performance should not be taken as an indication of future results and investors should conduct additional research and analysis to assess its growth potential and overall financial health before making their decisions.
More news about NeuroMetrix (NURO).
